John A. Mccoy Jr. - 01 Sep 2023 Form 3 Insider Report for ABBOTT LABORATORIES (ABT)

Role
VICE PRESIDENT
Signature
/s/ John A. McCoy, Jr. by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
01 Sep 2023
Net transactions value
$0
Form type
3
Filing time
06 Sep 2023, 18:48:27 UTC
Next filing
23 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABT Common shares without par value 15,215 01 Sep 2023 Direct
holding ABT Common shares without par value 55 01 Sep 2023 Profit Sharing Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABT Option (right to buy) 01 Sep 2023 Common Shares 13,369 $124.04 Direct F2
holding ABT Option (right to buy) 01 Sep 2023 Common Shares 16,632 $117.58 Direct F3
holding ABT Option (right to buy) 01 Sep 2023 Common Shares 12,759 $106.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2023.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,456 on February 19, 2022, 4,456 on February 19, 2023, and 4,457 on February 19, 2024.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,544 on February 18, 2023, 5,544 on February 18, 2024 and 5,544 on February 18, 2025.
F4 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,253 on February 17, 2024, 4,253 on February 17, 2025, and 4,253 on February 17, 2026.